Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
NNOX
Nano-X Imaging Ltd.
Directly manufactures diagnostic imaging equipment used for disease detection and monitoring.
|
$266.27M |
$4.54
+0.55%
|
|
ABEO
Abeona Therapeutics Inc.
ZEVASKYN is an autologous cell-based therapy (cell therapy) targeting RDEB wounds.
|
$264.08M |
$5.16
+5.74%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$263.11M |
$15.66
+1.69%
|
|
DDD
3D Systems Corporation
Offers dental equipment and dental 3D printing solutions (NextDent).
|
$261.64M |
$2.04
+1.24%
|
|
CVRX
CVRx, Inc.
CVRx's Barostim is a neuromodulation device (implantable) that modulates the autonomic nervous system via baroreflex activation for heart failure.
|
$257.07M |
$9.87
-1.20%
|
|
INZY
Inozyme Pharma, Inc.
Inozyme focuses on ENPP1 Deficiency, a rare disease, with INZ-701 as a lead therapy, making it a dedicated rare-disease biopharma company.
|
$256.96M |
$4.00
|
|
SLQT
SelectQuote, Inc.
Healthcare Services & Facilities encompasses SelectRx and other healthcare services provided via the platform.
|
$255.77M |
$1.49
+2.41%
|
|
PBYI
Puma Biotechnology, Inc.
Direct oncology biotech core product portfolio with Nerlynx and alisertib being cancer therapies.
|
$254.37M |
$5.06
+2.22%
|
|
TKNO
Alpha Teknova, Inc.
Teknova is the exclusive US/Canada manufacturer and distributor of the PluriFreeze PF10 cryopreservation system, a medical device.
|
$254.20M |
$4.76
+2.37%
|
|
MPAA
Motorcar Parts of America, Inc.
MPAA markets and sells diagnostic equipment, such as the JBT-1 Bench Top tester.
|
$253.90M |
$13.14
-1.68%
|
|
CADL
Candel Therapeutics, Inc.
CAN-2409 and CAN-3110 are viral vector-based therapies, aligning with gene therapy.
|
$253.62M |
$4.62
+3.47%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$249.07M |
$12.97
+0.12%
|
|
ACHV
Achieve Life Sciences, Inc.
Cytisinicline is an oral small-molecule therapeutic candidate for smoking cessation, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$247.35M |
$4.84
+5.56%
|
|
ZURA
Zura Bio Limited
Zura Bio develops immunology therapeutics for autoimmune and inflammatory diseases (Immunology Therapeutics).
|
$247.07M |
$3.79
+0.93%
|
|
SENS
Senseonics Holdings, Inc.
Senseonics develops and markets implantable medical devices and biometric sensing technologies (Eversense CGM), fitting the Medical Devices & Biometrics investable theme.
|
$246.03M |
$6.01
-0.08%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$243.98M |
$18.64
-1.84%
|
|
MGRM
Monogram Orthopaedics, Inc.
Direct product category: Monogram's system is a surgical device used in operating rooms for orthopedic procedures.
|
$243.79M |
$6.00
|
|
GNFT
Genfit S.A.
GENFIT's ELAFIBRONOR in Primary Biliary Cholangitis (PBC) represents a core liver-disease therapeutic offering.
|
$242.05M |
$4.90
+1.03%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$242.04M |
$3.07
+1.32%
|
|
IVA
Inventiva S.A.
Inventiva's lanifibranor is an orally administered small-molecule therapeutic for MASH, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$241.40M |
$4.61
+4.30%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$240.84M |
$0.60
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$237.27M |
$5.20
+13.04%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$237.22M |
$18.97
-5.10%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$230.25M |
$7.10
+1.72%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
OABI
OmniAb, Inc.
OmniAb's core offering is the Antibody Discovery Platform enabling rapid generation of human antibodies through engineered transgenic animals and associated discovery tools.
|
$228.22M |
$1.86
+0.27%
|
|
OWLT
Owlet, Inc.
Owlet sells FDA-cleared Medical Devices & Biometrics (Dream Sock and BabySat) with wearable biosensing capabilities.
|
$226.18M |
$13.21
+1.97%
|
|
SNFCA
Security National Financial Corporation
Death care services (cemetery and mortuary) are a direct service offering aligned with healthcare services and facilities.
|
$226.05M |
$8.72
+1.51%
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$223.54M |
$4.04
+1.76%
|
|
AIRS
AirSculpt Technologies, Inc.
AirSculpt provides premium, minimally invasive body contouring services through a network of centers, i.e., healthcare services and facilities.
|
$222.90M |
$3.56
-8.12%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$221.93M |
$6.21
+1.31%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$221.84M |
$2.61
+5.67%
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$221.65M |
$1.37
+11.38%
|
|
ELMD
Electromed, Inc.
Electromed manufactures the SmartVest Clearway airway clearance medical device, fitting the Medical Devices & Biometrics investable theme.
|
$221.42M |
$26.45
-4.44%
|
|
STXS
Stereotaxis, Inc.
Catheter-based cardiology devices (ablation/catheters) are a core direct product, fitting Cardiology Devices.
|
$220.29M |
$2.42
-2.02%
|
|
BNR
Burning Rock Biotech Limited
Burning Rock's brPROPHET MRD and MCED products are ctDNA-based diagnostics delivered as a liquid biopsy test.
|
$220.29M |
$21.48
+10.46%
|
Showing page 21 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
